Background/aims-Reducing oesophageal
acid exposure by suppressing acid secretion with omeprazole is highly effective in healing reflux oesophagitis. Some Results-Thirty per cent of patients failed to heal with the 20 mg dose. Unhealed patients had greater total 24 hour oesophageal acid exposure before treatment, and while receiving treatment also had greater acid exposure and a smaller reduction in acid exposure than did patients who healed. Forty seven per cent of the unhealed patients also failed to heal with the 40 mg dose. These patients had similar levels of acid exposure before treatment to those who healed, but had greater acid exposure while receiving treatment, particularly at night when supine.
Conclusions-Patients with severe ulcerative oesophagitis who are refractory to omeprazole have greater oesophageal acid exposure while receiving treatment than responding patients. This is due to a reduced responsiveness to acid suppression, and is likely to be an important factor underlying the failure of the oesophagitis to heal. (Gut 1996; 38: [649] [650] [651] [652] [653] [654] Keywords: gastro-oesophageal reflux, pH monitoring, gastric acid secretion, oesophagus.
The duration of oesophageal acid exposure is the most important factor determining the severity of reflux symptoms1 and the degree of oesophagitis2 3 Oesophageal pH monitoring Twenty four hour ambulatory oesophageal pH monitoring was performed using an antimony pH electrode (Synectics) positioned 5 cm above the manometrically determined lower oesophageal sphincter and connected to a portable digital recorder (Synectics Digitrapper Mark II 6100). Patients were requested to avoid drinking coffee, cordials, and fruit juices during the recording period. Omeprazole treatment was continued but patients were not allowed to take any antacid.
Clinical and laboratory assessment Symptoms were assessed by interview at entry and at four weekly intervals during the study. Heartburn, (day and night scored separately), regurgitation and dysphagia were graded as: 0 -none, 1 -mild, not interfering with usual activity; 2 -moderate, interfering with usual activity; and 3 -severe, incapacitating and preventing usual activity. Patients were specifically questioned about the occurrence of adverse events or symptoms. Compliance, assessed at each visit by capsule counts, was judged to be adequate only if at least 75% of the capsules had been consumed. Blood samples were taken for haematological and biochemical testing.
Data analysis
The pH data were analysed by computer (Synectics, Esophogram) for the duration pH<4 and the number of reflux episodes. Acid clearance time was calculated by dividing the duration pH<4 by the number of reflux episodes. Values were determined separately for the total 24 hours, and upright, supine, and three hour postprandial periods. Data for healed and unhealed patients were compared using the Mann-Whitney U test and are expressed in the text as median (interquartile range).
Results
Pre-treatment Sixty patients entered the study of which 59 received medication; one patient withdrew NSAID, non-steroidal anti-inflammatory drug.
Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis Values for pre-treatment upright, supine, and postprandial acid exposure, however, were similar in the two groups (Table II) . Pre-treatment acid clearance times were also similar in the two groups (healed: 1P7 min, 0.6-3.0 min; unhealed: 3v5 min, 2v6-5*1 min).
For patients who remained unhealed on 20 mg omeprazole and subsequently received the 40 mg dose, pre-treatment total, upright, supine, and postprandial oesophageal acid exposures were similar in those who eventually healed and those who remained unhealed (Table III, Fig 2) . Oesophageal acid clearance time before treatment was also similar in the healed patients (3.1 min, 2.6-6.2 min) to that in the unhealed patients (3.9 min, 3.5-5.9 min).
Phase 1: omeprazole 20 mg Seventeen patients failed to heal their oesophagitis after eight weeks' treatment with omeprazole 20 mg every morning. Total 24 hour oesophageal acid exposure while receiving treatment was significantly greater in those patients who failed to heal than in those who healed (Fig 1) , and significantly fewer unhealed patients fell within the normal range of <55% (4 of 17 patients v 27 of 38 patients, p<0005). The mean percentage fall in total acid exposure with treatment in the unhealed patients (45%) was significantly less than that in the healed patients (82%), p<002). Unhealed patients also had greater levels of upright, supine, and postprandial reflux during treatment than did those who healed (Table II) .
Most patients (47 of 55) were rendered symptom free after eight weeks of treatment. The prevalence of complete symptom relief in the patients who did not heal (15 of 17 patients) was similar to that in those who healed (32 and four of six unhealed patients were rendered asymptomatic; two unhealed patients had residual mild heartburn (grade 1). During treatment total oesophageal acid exposure was significantly greater in those patients who failed to heal than in those who healed (Fig 2) , and all unhealed patients had acid exposures above 50/o (range 10.3-21.8%) compared with only one of eight healed patients. Upright acid exposure was similar in the healed and unhealed patients while receiving 20 mg omeprazole but was significantly greater in the unhealed patients with the 40 mg dose (Table III) . Supine acid exposure, however, was significantly greater in the unhealed patients during treatment with both the 20 mg dose and 40 mg dose. Postprandial acid exposure was similar in the healed and unhealed patients with both the 20 mg and 40 mg doses.
Discussion
In this study we evaluated prospectively the relation between oesophageal acid exposure and healing of oesophagitis in patients with severe reflux oesophagitis treated with omeprazole. Our data show that failure of oesophagitis to heal is associated with a higher level of oesophageal acid exposure before treatment, and higher levels of acid exposure while receiving omeprazole because of a smaller reduction in acid exposure, particularly at night. These findings are consistent with the hypothesis that failure of oesophagitis to heal with omeprazole is due to inadequate acid suppression.
Severity of oesophagitis as judged by endoscopy before treatment is the most important * (74. factor determining the response to treatment with acid suppressant drugs.4 6 7 18 19 We selected patients with severe reflux oesophagitis as we have shown previously that such patients are more refractory to omeprazole than patients with lesser degrees of oesophagitis.6 Most of the patients had proved refractory to H2 receptor antagonists. The healing rate with the 20 mg dose in this study (69%) is comparable to that seen previously,6
and illustrates the difficulty in treating patients with severe oesophagitis even with potent acid suppressants. In contrast with earlier studies, however, which reported similar healing rates with 20 mg and 40 mg doses,6 8 doubling the dose of omeprazole from 20 mg to 40 mg in this study was associated with healing of the oesophagitis in an additional 15% of the patients. This increase in healing rate may have been a result of a longer duration of treatment in the patients who received the 40 mg dose as these patients had already received eight weeks' treatment with the 20 mg dose; in the previous studies, patients received only eight weeks' treatment overall. The important finding from this study was that failure of oesophagitis to heal was associated with higher levels of acid exposure on treatment. There are two main explanations for this finding. Firstly, patients that remained unhealed on the 20 mg dose had higher levels of acid exposure before treatment that patients who did not heal may have different patterns of acid secretion. Despite the confounding factor of H2 antagonists, however, differences in reflux patterns cannot account for the failure of patients to respond to the higher dose of omeprazole as the pre-treatment oesophageal acid exposure levels in these patients were no different from those in the patients who healed with this dose.
Secondly, and more importantly, our data suggest that failure of oesophagitis to heal is associated with lower degrees of acid suppression. Patients who did not heal with the 20 mg dose not only had higher levels of acid exposure while receiving treatment but also had a significantly smaller reduction in acid exposure. Additionally, patients that remained unhealed with the 40 mg dose had substantially higher levels of acid exposure on treatment despite similar pretreatment levels of acid exposure to those in patients who healed. Although we did not measure gastric acid secretion, these findings are best explained by a relative refractoriness to acid suppression with omeprazole in a subgroup of patients with severe oesophagitis. The Oesophageal acid exposure was not the only determinant of healing. Some patients healed despite continuing high levels of acid exposure, and some patients failed to heal despite reduction of acid exposure to below normal levels. Aspirin use has been implicated as a significant factor in the resistance of oesophagitis treatment.34 As with other studies, however, 6 8 smoking or the use of non-steroidal antiinflammatory drugs including aspirin did not affect the rate ofhealing. Increased exposure to bile salts has been reported in patients with severe reflux disease.35 Whether patients who are refractory to omeprazole have greater oesophageal exposure to these agents, however, remains to be determined.
In summary we have shown that failure of severe oesophagitis to heal with omeprazole is associated with persistence of a high level of oesophageal acid exposure that is most consistent with inadequate suppression of acid secretion. The mechanisms underlying this apparent refractoriness require further investigation. Our findings also underline the need in patients with severe reflux disease to titrate the dose of omeprazole to achieve adequate acid suppression, and that oesophageal pH monitoring is a useful guide for this approach. The apparent breakthrough of nocturnal acid secretion in refractory patients may be just related to dose. Whether or not night time compared with morning dosing,30 or dividing the single 40 mg dose into twice daily 20 mg doses37 would achieve better healing awaits further study.
